OncBioMune Pharmaceuticals has reported an ongoing review of its Phase II clinical trial protocol by the regulatory committee at Beth Israel Deaconess Medical Centre / Harvard Medical School in the US for evaluation of ProscaVax to treat early stage prostate cancer.

ProscaVax is being developed by the firm as a therapeutic vaccine to potentially become the standard-of-care treatment for prostate cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The immunotherapeutic cancer vaccine combines tumour-associated prostate specific antigen (PSA) with biological adjuvants, interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Designed to assess the safety, tolerability and efficacy of ProscaVax, the Phase II trial will enrol newly diagnosed, treatment-naïve patients who have agreed to avoid standard approved therapies such as radical prostatectomy, radiation or brachytherapy.

OncBioMune CEO Dr Jonathan Head said: “The regulatory committee is a component of the Institutional Review Board and integral to the protocol approval process to commence the study.

See Also:

"The regulatory committee is a component of the Institutional Review Board and integral to the protocol approval process to commence the study."

“I interpret the protocol now being in their hands as a signal that we are getting close to conducting the first ever trial of ProscaVax as a front-line treatment for prostate cancer.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firm has already obtained data from a Phase I/II trial of ProscaVax conducted in 12 prostate cancer patients administered initially with six vaccinations.

Upon measurement of serum PSA concentrations after three to four weeks following the sixth vaccination, it was found that two-thirds of the patients experienced decreased PSAs.

In addition to the Phase II trial for early stage prostate cancer, the firm plans to commence a Phase II/III trial for patients with late-stage prostate cancer in Mexico.